Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 15/20 | 0.68 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.68 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.64 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15810652 | 1.00 | P2RY6 (0.68) | P2RY6P2RY2DNPH1P2RY4 | |
| SCHEMBL18852479 | 1.00 | P2RY6 (0.68) | P2RY6P2RY2DNPH1P2RY4 | |
| SCHEMBL12714926 | 0.91 | P2RY6 (0.72) | P2RY6P2RY2DNPH1P2RY4 | |
| SCHEMBL15065276 | 0.91 | P2RY6 (0.72) | P2RY6P2RY2DNPH1P2RY4 | |
| SCHEMBL15065277 | 0.91 | P2RY6 (0.72) | P2RY6P2RY2DNPH1P2RY4 | |
| SCHEMBL3469716 | 0.91 | DNPH1 (0.77) | P2RY6P2RY2DNPH1 | |
| SCHEMBL17979616 | 0.89 | DNPH1 (0.81) | P2RY6P2RY2DNPH1P2RY4 | |
| SCHEMBL14929299 | 0.89 | DNPH1 (0.81) | P2RY6P2RY2DNPH1P2RY4 | |
| SCHEMBL14946379 | 0.89 | DNPH1 (0.81) | P2RY6P2RY2DNPH1P2RY4 | |
| SCHEMBL25722701 | 0.89 | DNPH1 (0.81) | P2RY6P2RY2DNPH1P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Modema Therapeutics, Inc. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20160354492-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160354491-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160348099-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160354492-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | P2RY6 1545/4885P2RY2 2899/4885DNPH1 1736/4885 |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | P2RY6 1545/4885P2RY2 2899/4885DNPH1 1736/4885 |
| US-20160348099-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | P2RY6 1545/4885P2RY2 2899/4885DNPH1 1736/4885 |
| US-20160354491-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | P2RY6 1545/4885P2RY2 2899/4885DNPH1 1736/4885 |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | P2RY6 2112/4885P2RY2 2786/4885DNPH1 2277/4885 |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | P2RY6 2112/4885P2RY2 2786/4885DNPH1 2277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.